CD30 CAR-T in the Treatment of CD30 Positive Relapsed/Refractory Lymphoma
NCT06850285
·
clinicaltrials.gov ↗
NA
Phase
RECRUITING
Status
15
Enrollment
OTHER
Sponsor class
Conditions
Lymphoma, B-Cell
Interventions
DRUG:
chimeric antigen receptor gene modified T cells
Sponsor
Shanxi Bethune Hospital